Invention Grant
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/docs/US/2017-11-07/US09809590B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
-
Application No.: US14858029Application Date: 2015-09-18
-
Publication No.: US09809590B2Publication Date: 2017-11-07
- Inventor: Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsater , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
- Applicant: Array BioPharma Inc.
- Applicant Address: US CO Boulder
- Assignee: Array BioPharma Inc.
- Current Assignee: Array BioPharma Inc.
- Current Assignee Address: US CO Boulder
- Agency: Viksnins Harris Padys Malen LLP
- Agent Sarah S. Mastous
- Main IPC: C07D471/04
- IPC: C07D471/04 ; A61K45/06 ; A61K31/496
![Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors](/abs-image/US/2017/11/07/US09809590B2/abs.jpg.150x150.jpg)
Abstract:
Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
Public/Granted literature
Information query
